These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18923918)

  • 1. Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively.
    Bagewadi S; Roberts J; Mercer J; Jones S; Stephenson J; Wraith JE
    J Inherit Metab Dis; 2008 Dec; 31(6):733-7. PubMed ID: 18923918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
    Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
    Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy in the home setting for mucopolysaccharidosis VI: a survey of patient characteristics and physicians' early findings in the United States.
    Tifft C; Proud V; Levy P; DeMarco K; Nicely H; Turbeville S
    J Infus Nurs; 2009; 32(1):45-52. PubMed ID: 19142150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders.
    Miebach E
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S100-6. PubMed ID: 20040319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Home treatment in paediatric patients with Hunter syndrome: the first Italian experience.
    Ceravolo F; Mascaro I; Sestito S; Pascale E; Lauricella A; Dizione E; Concolino D
    Ital J Pediatr; 2013 Sep; 39():53. PubMed ID: 24011228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Enzyme replacement therapy of lysosomal storage diseases].
    Germain DP; Boucly C; Carlier RY; Caudron E; Charlier P; Colas F; Jabbour F; Martinez V; Mokhtari S; Orlikowski D; Pellegrini N; Perronne C; Prigent H; Rubinsztajn R; Benistan K
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S279-91. PubMed ID: 21211680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]).
    Kim KH; Decker C; Burton BK
    Pediatrics; 2008 Mar; 121(3):e714-7. PubMed ID: 18250117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB.
    Drugs R D; 2005; 6(5):312-5. PubMed ID: 16128602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy for the management of the mucopolysaccharidoses.
    Wraith JE
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S63-5. PubMed ID: 20040314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey.
    Burton BK; Guffon N; Roberts J; van der Ploeg AT; Jones SA;
    Mol Genet Metab; 2010; 101(2-3):123-9. PubMed ID: 20638311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats.
    Auclair D; Finnie J; Walkley SU; White J; Nielsen T; Fuller M; Cheng A; O'Neill CA; Hopwood JJ
    Pediatr Res; 2012 Jan; 71(1):39-45. PubMed ID: 22289849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
    Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.
    Muñoz-Rojas MV; Horovitz DD; Jardim LB; Raymundo M; Llerena JC; de Magalhães Tde S; Vieira TA; Costa R; Kakkis E; Giugliani R
    Mol Genet Metab; 2010 Apr; 99(4):346-50. PubMed ID: 20036175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parental experience of enzyme replacement therapy for Hunter syndrome.
    Buraczewska M; O'Leary D; Walsh O; Monavari A; Crushell E
    Ir Med J; 2013 Apr; 106(4):120-2. PubMed ID: 23691848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
    Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
    Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI.
    Bielicki J; Crawley AC; Davey RC; Varnai JC; Hopwood JJ
    J Biol Chem; 1999 Dec; 274(51):36335-43. PubMed ID: 10593925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI.
    Harmatz PR; Garcia P; Guffon N; Randolph LM; Shediac R; Braunlin E; Lachman RS; Decker C
    J Inherit Metab Dis; 2014 Mar; 37(2):277-87. PubMed ID: 24108527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis?
    Pitz S; Ogun O; Arash L; Miebach E; Beck M
    Graefes Arch Clin Exp Ophthalmol; 2009 Jul; 247(7):975-80. PubMed ID: 19159944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.